Compound 28i

1 paper5 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Innovative Research Team of High-level Local University in Shanghai and 3 more

Animals1

Outcomes

MDH2

downin cells1

1 study

Compound 28i inhibits MDH2 in cells.
“compound 28i, a potent MDH2 inhibitor”
Cells
Discovery of Novel MDH2 Inhibitor 28i by Secondary Development of Glibenclamide with Potent Antiaging Activities
Journal of medicinal chemistry22 Jan 2026

Latest

1 in 12 months

Journal of Medicinal Chemistry23 Jan

Discovery of Novel MDH2 Inhibitor 28i by Secondary Development of Glibenclamide with Potent Antiaging Activities

Experiments in wormsInterventions

Paper

Compound 28i

Outcomes

Latest

Discovery of Novel MDH2 Inhibitor 28i by Secondary Development of Glibenclamide with Potent Antiaging Activities

Related